Addex Therapeutics' Financial Activities in 2025
Addex Therapeutics (SWX: ADXN), a biopharmaceutical company focused on developing small molecule allosteric modulators for neurological disorders, announced significant financial results for the half year of 2025. As of June 30, 2025, the company’s cash position stood at CHF 2.3 million. This position outlines the foundation for advancing its promising drug projects aimed at treating neurological conditions.
Progress in Drug Development
A standout development has been the GABAB PAM candidate, which has exhibited strong anti-tussive activity in chronic cough disease models. The ongoing research indicates a positive trajectory as the company responds to patient needs through innovative therapies.
Strategic Partnerships and Innovations
Addex has regained rights to its Phase 2 mGlu2 PAM asset, ADX71149, demonstrating its commitment to developing this treatment further. Additionally, the company is exploring new opportunities to enhance its treatment portfolio. This includes entering an option agreement with Sinntaxis for exclusive access to crucial intellectual property regarding the use of mGlu5 NAM in brain injury recovery.
Furthermore, the collaboration with Indivior is crucial as they advance their GABAB PAM substance use disorder program through IND enabling studies. Such partnerships are vital for validating Addex's integrated approach to drug discovery and development.
Significant Financial Data from H1 2025
During the first half of 2025, Addex reported a decrease in income, dropping to CHF 0.1 million compared to CHF 0.3 million in 2024 largely due to the conclusion of an R&D collaboration with Indivior. Research and development expenses have also seen a decrease, further reflecting the company's strategic operational management.
Overview of Financial Statistics
The G&A expenses reduced by CHF 0.4 million compared to the previous year, attributed to cuts in legal costs. On the other hand, conversely, the net loss saw a rise in net loss from continuing operations to CHF 1.9 million, an increase partially owing to losses linked with investments in its associate Neurosterix.
The reported basic and diluted loss per share was CHF 0.03 for the half-year period, a contrasting result to the profit per share of CHF 0.10 recorded for the same time last year.
Commitment to Advancing Treatment Options
Addex Therapeutics has remained focused on reducing cash burn while continuing to advance its leading drug candidates. As of the end of June 2025, the company has managed its operational framework effectively, reflecting its dedication to sustainability in research-oriented financial structures. As a clinical-stage organization, Addex strives to adapt quickly and effectively, maintaining its status in the evolving biopharmaceutical landscape.
Involvement in Neurodevelopmental Disorders
The recent investment in Stalicla SA further emphasizes Addex's targeted efforts to support innovative treatments for central nervous system (CNS) disorders. This strategy not only strengthens Addex’s protocol for comprehensive approaches to therapeutic solutions but also opens avenues for future growth through pioneering partnerships.
Conclusion and Future Outlook
Overall, Addex Therapeutics’ financial results for the first half of 2025 showcase the company's robust commitment to addressing substantial healthcare needs through pioneering drug development in neurological disorders. As it continues to pursue strategic partnerships and innovative research projects, Addex positions itself favorably for ongoing advancements in the pharmaceutical sector.
Frequently Asked Questions
What are the primary focuses of Addex Therapeutics?
Addex Therapeutics is mainly focused on developing allosteric modulators for neurological disorders, particularly in areas like chronic cough and substance use disorders.
How has Addex's financial performance changed in the first half of 2025?
Addex experienced a decrease in income during the first half of 2025 compared to the same period in 2024, primarily due to the conclusion of an R&D collaboration.
What advancements has Addex made with its drug candidates?
Addex has made significant progress with its GABAB PAM chronic cough candidate, showcasing strong anti-tussive activity in disease models.
Who is Addex's partner in substance use disorder programs?
Indivior is currently a key partner advancing the GABAB PAM program for substance use disorders through IND enabling studies.
What is the cash position of Addex as of June 30, 2025?
Addex holds a cash position of CHF 2.3 million at the end of the first half of 2025, reflecting its financial strategy and operational management.
